Boston’s biotech identity is under pressure as founders decamp for California, Alzheimer’s researchers uncover more secrets of tau function, and Replimune finally secures a hard-fought FDA approval. Boston is giving up ground to SFBoston keeps insisting it’s the biotech capital of the world, and it still has a very good case to make. “There’s some crazy experiments that we’re currently running … that I probably would not have thought about when I was in Boston,” Wong said. His company, Integrated Biosciences, is just one startup, but it embodies a broader anxiety hanging over Massachusetts as AI reshapes biotech. Subtle Medicare policy shift could delay drug price negotiationsA subtle Trump administration policy change may have handed AbbVie years of additional pricing power, STAT’s Ed Silverman writes.